Treatment Patterns and Differences in Survival of Non-Small Cell Lung Cancer Patients Between Academic and Non-Academic Hospitals in the Netherlands
Clinical Lung Cancer , Volume 18 - Issue 5 p. e341- e347
Non-small cell lung cancer (NSCLC) survival is compared between patients treated in all academic (n = 1289) versus all non-academic (n = 12,698) Dutch hospitals, using Kaplan-Meier estimates and a Cox proportional hazards model. For 1009 patients, treatment patterns are described. Diagnosis in an academic hospital is associated with decreased mortality. Possibilities for improvement of NSCLC care are suggested. Background The aims of this study are to analyze differences in survival between academic and non-academic hospitals and to provide insight into treatment patterns for non-small cell lung cancer (NSCLC). Results show the state of NSCLC survival and care in the Netherlands. Methods The Netherlands Cancer Registry provided data on NSCLC survival for all Dutch hospitals. We used the Kaplan-Meier estimate to calculate median survival time by hospital type and a Cox proportional hazards model to estimate the relative risk of mortality (expressed as hazard ratios) for patients diagnosed in academic versus non-academic hospitals, with adjustment for age, gender, and tumor histology, and stratifying for disease stage. Data on treatment patterns in Dutch hospitals was obtained from 4 hospitals (2 academic, 2 non-academic). A random sample of patients diagnosed with NSCLC from January 2009 until January 2011 was identified through hospital databases. Data was obtained on patient characteristics, tumor characteristics, and treatments. Results The Cox proportional hazards model shows a significantly decreased hazard ratio of mortality for patients diagnosed in academic hospitals, as opposed to patients diagnosed in non-academic hospitals. This is specifically true for primary radiotherapy patients and patients who receive systemic treatment for non-metastasized NSCLC. Conclusion Patients diagnosed in academic hospitals have better median overall survival than patients diagnosed in non-academic hospitals, especially for patients treated with radiotherapy, systemic treatment, or combinations. This difference may be caused by residual confounding since the estimates were not adjusted for performance status. A wide variety of surgical, radiotherapeutic, and systemic treatments is prescribed.
|, , , ,
|Clinical Lung Cancer
|Institute for Medical Technology Assessment (iMTA)
van der Linden, N., Bongers, M., Coupé, V., Smit, E., Groen, H., Welling, A., … Uyl-de Groot, C. (2017). Treatment Patterns and Differences in Survival of Non-Small Cell Lung Cancer Patients Between Academic and Non-Academic Hospitals in the Netherlands. Clinical Lung Cancer, 18(5), e341–e347. doi:10.1016/j.cllc.2015.11.011